IGM Biosciences to be acquired by Concentra for $1.247/share plus CVR

IGM Biosciences, Inc.

Concentra will acquire all IGMS common stock for $1.247 cash plus one CVR per share.
CVR gives holders 100% of closing net cash above $82M and 80% of product/IP sale proceeds within one year.
Board unanimously approved; tender offer must commence within 10 business days; closing no later than Sept 29, 2025.
CFO Misbah Tahir, PAO Steven Weber, and CBO Lisa Decker to depart in July/August 2025; CEO departure expected at closing.
Termination fee of $2.425M payable by IGMS in certain break scenarios; no financing condition for Concentra.

item 1.01item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.